BMY vs GSK: stock comparison and AI forecast
Bristol Myers Squibb Co (BMY) and Gsk Plc (GSK) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMY Bristol Myers Squibb Co
- Market Cap
- $126.14B
- P/E Ratio
- 13.7x
- Size
- large-cap
- AI Forecast
GSK Gsk Plc
- Market Cap
- $99.12B
- P/E Ratio
- 5.4x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BMY is 1.3 times larger than GSK by market capitalization ($126.14B against $99.12B).
- GSK trades at 5.4 times trailing earnings, BMY at 13.7 times.
- BMY carries 2.79 times debt per unit of equity, against 2.76 times for GSK.
- BMY yields 4.06% in dividends; GSK pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMY | GSK |
|---|---|---|
| Market Cap | $126.14B | $99.12B |
| P/E Ratio | 13.65x | 5.41x |
| P/B Ratio | 5.39x | – |
| Dividend Yield | 4.06% | – |
| EPS | $4.52 | $9.08 |
| Book Value/Share | $11.45 | – |
| Revenue/Share | $24.48 | $81.00 |
| FCF/Share | $4.54 | $15.23 |
Profitability & Margins
| Metric | BMY | GSK |
|---|---|---|
| ROE | 39.5% | – |
| ROA | 10.4% | – |
| Gross Margin | 69.2% | 70.8% |
| Operating Margin | – | 20.3% |
| Net Margin | 18.5% | – |
| EBT Margin | 22.6% | 18.2% |
| Tax Rate | 18.4% | 13.7% |
Financial Health
| Metric | BMY | GSK |
|---|---|---|
| Current Ratio | 1.59x | 0.82x |
| Quick Ratio | 1.44x | 0.54x |
| D/E Ratio | 2.79x | 2.76x |
| Financial Leverage | 3.79x | – |
| Interest Coverage | 42.5x | – |
| Working Capital | $11.01B | -$5.23B |
Cash Flow
| Metric | BMY | GSK |
|---|---|---|
| Operating Cash Flow | $10.65B | $37.61B |
| Free Cash Flow | $9.29B | $30.73B |
| Capital Spending | -$1.37B | -$6.88B |
| OCF Growth YoY | -35.9% | -13.3% |
| FCF Growth YoY | -39.3% | 0.0% |
| FCF/Sales | 18.6% | 18.8% |
| CapEx/Sales | 2.7% | 4.2% |
Operational Efficiency
| Metric | BMY | GSK |
|---|---|---|
| Asset Turnover | 0.56x | – |
| Receivables Turnover | 5.4x | 16.6x |
| Inventory Turnover | 5.7x | 6.1x |
| Fixed Assets Turnover | 6.3x | 13.3x |
| Days Sales Outstanding | 67 days | 22 days |
| Days Inventory | 64 days | 60 days |
| Payables Period | 110 days | 155 days |
| Cash Conversion Cycle | 21 days | -73 days |
Income Statement
| Metric | BMY | GSK |
|---|---|---|
| Total Revenue | $50.03B | $163.43B |
| Operating Income | – | $33.20B |
| Net Income | $9.24B | – |
| R&D Expense | $10.56B | $33.87B |
| SG&A Expense | $7.32B | $50.02B |
| Cost of Goods Sold | $15.39B | $47.81B |
Dividend & Shareholder Information
| Metric | BMY | GSK |
|---|---|---|
| Dividends Per Share | $2.50 | – |
| Payout Ratio | 55.3% | – |
| Shares Outstanding | 2044M | 2017M |
| Net Income Growth | 53.1% | – |
| EPS Growth | 52.2% | 87.6% |
BMY vs GSK: stock comparison and AI forecast
Which is bigger, BMY or GSK?
BMY is 1.3 times larger than GSK by market capitalization ($126.14B against $99.12B).
Which is cheaper on earnings, BMY or GSK?
GSK trades at 5.4 times trailing earnings, BMY at 13.7 times.
Which one does Intratio's AI model rank higher, BMY or GSK?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.